Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban

被引:39
作者
Winkle, Roger A. [1 ,2 ]
Mead, R. Hardwin [1 ,2 ]
Engel, Gregory [1 ,2 ]
Kong, Melissa H. [1 ,2 ]
Patrawala, Rob A. [1 ,2 ]
机构
[1] Silicon Valley Cardiol, East Palo Alto, CA 94303 USA
[2] Sequoia Hosp, Redwood City, CA USA
来源
EUROPACE | 2014年 / 16卷 / 10期
关键词
Atrial fibrillation; Ablation; Dabigatran; Rivaroxaban; Warfarin; Anticoagulation; INTERNATIONAL NORMALIZED RATIO; CATHETER ABLATION; RADIOFREQUENCY ABLATION; MANAGEMENT; SAFETY; COMPLICATIONS; METAANALYSIS; STRATEGIES; EFFICACY; IMPROVES;
D O I
10.1093/europace/euu196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Atrial fibrillation ablation requires peri-procedural oral anticoagulation (OAC) to prevent thromboembolic events. There are several options for OAC. We evaluate peri-procedural AF ablation complications using a variety of periprocedural OACs. Methods and results We examined peri-procedural OAC and groin, bleeding, and thromboembolic complications for 2334 consecutive AF ablations using open irrigated-tip radiofrequency (RF) catheters. Pre-ablation OAC was warfarin in 1113 (47.7%), dabigatran 426 (18.3%), rivaroxaban 187 (8.0%), aspirin 472 (20.2%), and none 136 (5.8%). Oral anticoagulation was always interrupted and intraprocedural anticoagulation was unfractionated heparin (activated clotting time, ACT = 237 +/- 26 s). Pre-and post-OAC drugs were the same for 1591 (68.2%) and were different for 743 (31.8%). Following ablation, 693 (29.7%) were treated with dabigatran and 291 (12.5%) were treated with rivaroxaban. There were no problems changing from one OAC pre-ablation to another post-ablation. Complications included 12 (0.51%) pericardial tamponades [no differences for dabigatran (P = 0.457) or rivaroxaban (P = 0.163) compared with warfarin], 12 (0.51%) groin complications [no differences for rivaroxaban (P = 0.709) and fewer for dabigatran (P = 0.041) compared with warfarin]. Only 5 of 2334 (0.21%) required blood transfusions. There were two strokes (0.086%) and no transient ischaemic attacks (TIAs) in the first 48 h post-ablation. Three additional strokes (0.13%), and two TIAs (0.086%) occurred from 48 h to 30 days. Only one stroke had a residual deficit. Compared with warfarin, the neurologic event rate was not different for dabigatran (P = 0.684) or rivaroxaban (P = 0.612). Conclusion Using interrupted OAC, low target intraprocedural ACT, and irrigated-tip RF, the rate of peri-procedural groin, haemorrhagic, and thromboembolic complications was extremely low. There were only minimal differences between OACs. Low-risk patients may remain on aspirin/no OAC pre-ablation. There are no problems changing from one OAC pre-ablation to another post-ablation.
引用
收藏
页码:1443 / 1449
页数:7
相关论文
共 24 条
  • [1] Comparative Safety of Periablation Anticoagulation Strategies for Atrial Fibrillation: Data from a Large Multicenter Study
    Arshad, Aysha
    Johnson, Christopher K.
    Mittal, Suneet
    Buch, Eric
    Hamam, Ismail
    Thanh Tran
    Shaw, Richard E.
    Musat, Dan
    Preminger, Mark
    Sichrovsky, Tina
    Herweg, Bengt
    Shivkumar, Kalyanam
    Hummel, John
    Steinberg, Jonathan S.
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2014, 37 (06): : 665 - 673
  • [2] Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
    Bin Abdulhak, Aref A.
    Khan, Abdur Rahman
    Tleyjeh, Imad M.
    Spertus, John A.
    Sanders, Susan U.
    Steigerwalt, Kristy E.
    Garbati, Musa A.
    Bahmaid, Reem A.
    Wimmer, Alan P.
    [J]. EUROPACE, 2013, 15 (10): : 1412 - 1420
  • [3] Warfarin Is Not Needed in Low-Risk Patients Following Atrial Fibrillation Ablation Procedures
    Bunch, T. Jared
    Crandall, Brian G.
    Weiss, J. Peter
    May, Heidi T.
    Bair, Tami L.
    Osborn, Jeffrey S.
    Anderson, Jeffrey L.
    Lappe, Donald L.
    Muhlestein, J. Brent
    Nelson, Jennifer
    Allison, Scott
    Foley, Thomas
    Anderson, Lars
    Day, John D.
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2009, 20 (09) : 988 - 993
  • [4] HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up
    Calkins, Hugh
    Brugada, Josep
    Packer, Douglas L.
    Cappato, Riccardo
    Chen, Shih-Ann
    Crijns, Harry J. G.
    Damiano, Ralph J., Jr.
    Davies, D. Wyn
    Haines, David E.
    Haissaguerre, Michel
    Lesaka, Yoshito
    Jackman, Warren
    Jais, Pierre
    Kottkamp, Hans
    Kuck, Karl Heinz
    Lindsay, Bruce D.
    Marchlinski, Francis E.
    McCarthy, Patrick M.
    Mont, J. Lluis
    Morady, Fred
    Nademanee, Koonlawee
    Natale, Andrea
    Pappone, Carlo
    Prystowsky, Eric
    Raviele, Antonio
    Ruskin, Jeremy N.
    Shemin, Richard J.
    [J]. EUROPACE, 2007, 9 (06): : 335 - 379
  • [5] Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation
    Di Biase, Luigi
    Burkhardt, J. David
    Mohanty, Prasant
    Sanchez, Javier
    Horton, Rodney
    Gallinghouse, G. Joseph
    Lakkireddy, Dhanunjay
    Verma, Atul
    Khaykin, Yaariv
    Hongo, Richard
    Hao, Steven
    Beheiry, Salwa
    Pelargonio, Gemma
    Dello Russo, Antonio
    Casella, Michela
    Santarelli, Pietro
    Santangeli, Pasquale
    Wang, Paul
    Al-Ahmad, Amin
    Patel, Dimpi
    Themistoclakis, Sakis
    Bonso, Aldo
    Rossillo, Antonio
    Corrado, Andrea
    Raviele, Antonio
    Cummings, Jennifer E.
    Schweikert, Robert A.
    Lewis, William R.
    Natale, Andrea
    [J]. CIRCULATION, 2010, 121 (23) : 2550 - 2556
  • [6] Rates of hemorrhage during warfarin therapy for atrial fibrillation
    Gomes, Tara
    Mamdani, Muhammad M.
    Holbrook, Anne M.
    Paterson, J. Michael
    Hellings, Chelsea
    Juurlink, David N.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (02) : E121 - E127
  • [7] Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature
    Hohnloser, Stefan H.
    Camm, A. John
    [J]. EUROPACE, 2013, 15 (10): : 1407 - 1411
  • [8] Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: A safe and efficacious periprocedural anticoagulation strategy
    Hussein, Ayman A.
    Martin, David O.
    Saliba, Walid
    Patel, Deven
    Karim, Saima
    Batal, Omar
    Banna, Mustafa
    Williams-Andrews, Michelle
    Sherman, Minerva
    Kanj, Mohamed
    Bhargava, Mandeep
    Dresing, Thomas
    Callahan, Thomas
    Tchou, Patrick
    Di Biase, Luigi
    Beheiry, Salwa
    Lindsay, Bruce
    Natale, Andrea
    Wazni, Oussama
    [J]. HEART RHYTHM, 2009, 6 (10) : 1425 - 1429
  • [9] Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
    Lakkireddy, Dhanunjaya
    Reddy, Yeruva Madhu
    Di Biase, Luigi
    Vallakati, Ajay
    Mansour, Moussa C.
    Santangeli, Pasquale
    Gangireddy, Sandeep
    Swarup, Vijay
    Chalhoub, Fadi
    Atkins, Donita
    Bommana, Sudharani
    Verma, Atul
    Sanchez, Javier E.
    Burkhardt, J. David
    Barrett, Conor D.
    Baheiry, Salwa
    Ruskin, Jeremy
    Reddy, Vivek
    Natale, Andrea
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (10) : 982 - 988
  • [10] Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint
    O'Neill, Mark D.
    Wright, Matthew
    Knecht, Sebastien
    Jais, Pierre
    Hocini, Meleze
    Takahashi, Yoshihide
    Joensson, Anders
    Sacher, Frederic
    Matsuo, Seiichiro
    Lim, Kang Teng
    Arantes, Leonardo
    Derval, Nicolas
    Lellouche, Nicholas
    Nault, Isabelle
    Bordachar, Pierre
    Clementy, Jacques
    Haissaguerre, Michel
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (09) : 1105 - 1112